logo
Book a meeting
RenovoRx

Renovo Rx

Biotechnology, 4546 El Camino Real, Los Altos, California, 94022, United States, 1-10 Employees

renovorx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 65********

Who is RENOVORX

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial ...

Read More

lock icon Get Full Access
map
  • 4546 El Camino Real, Los Altos, California, 94022, United States Headquarters: 4546 El Camino Real, Los Altos, California, 94022, United States
  • 2009 Date Founded: 2009
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies
  • Shaun Bagai CEO:   Shaun Bagai

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from RENOVORX

RenovoRx Org Chart and Mapping

Shaun Bagai

Shaun Bagai

CEO

Employees
Jessica Morse

Jessica Morse

Executive Administrative Assistant

Charlie Wu

Charlie Wu

Operations Manager

See Full Org Chart arrow
email-formate-icon
View Email Formats for RenovoRx
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding RenovoRx

Answer: RenovoRx's headquarters are located at 4546 El Camino Real, Los Altos, California, 94022, United States

Answer: RenovoRx's phone number is 65********

Answer: RenovoRx's official website is https://renovorx.com

Answer: RenovoRx's revenue is $1 Million to $5 Million

Answer: RenovoRx's SIC: 2834

Answer: RenovoRx's NAICS: 325412

Answer: RenovoRx has 1-10 employees

Answer: RenovoRx is in Biotechnology

Answer: RenovoRx contact info: Phone number: 65******** Website: https://renovorx.com

Answer: RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRxs patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access